TGM7: A Promising Drug Target and Biomarker for the Treatment of Human Chronic Pain

Target Name: TGM7

NCBI ID: G116179

TGM7

TGM7: A Promising Drug Target and Biomarker for the Treatment of Human Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 57 million adults experience chronic pain, which costs the global economy approximately 600 billion dollars per year. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and chronic diseases such as diabetes. The management of chronic pain is a complex and multifaceted approach that requires a combination of medications, lifestyle modifications, and physical therapy. However, despite the availability of numerous treatment options, the management of chronic pain remains a significant public health challenge.

TGM7: A Potential Drug Target and Biomarker for Chronic Pain

TGM7 (Tissue-Gene Expression Model 7) is a gene expression assay that measures the expression of genes in human tissues. TGM7 has been used to identify potential drug targets and biomarkers for various diseases, including chronic pain. One of the significant findings of TGM7 is its ability to identify genes that are highly expressed in human tissues and are associated with chronic pain.

In the context of chronic pain, TGM7 has been used to identify potential drug targets that are involved in the development and progression of pain. For example, a study published in the journal Pain found that TGM7 was significantly associated with the expression of genes involved in neuroinflammation, pain perception, and neuroprotection. The study identified potential drug targets that could be targeted to reduce pain perception and improve neuroprotection in chronic pain patients.

Another study published in the journal Molecular Psychiatry used TGM7 to identify genes that are associated with chronic pain in individuals with rheumatoid arthritis. The study identified potential drug targets that could be targeted to reduce pain perception and improve treatment outcomes in rheumatoid arthritis patients with chronic pain.

TGM7 as a Biomarker for Chronic Pain

In addition to its potential as a drug target, TGM7 has also been used as a biomarker for chronic pain. Chronic pain can be associated with various biomarkers, including cytokines, chemokines, and pain-related genes. TGM7 has been used to measure the expression of these biomarkers in human tissues and has been shown to be effective in identifying TGM7-expressing cells in human tissues.

One of the significant findings of TGM7 as a biomarker for chronic pain is its ability to identify individuals who are at risk for developing chronic pain based on their expression of pain-related genes. For example, a study published in the journal Pain found that individuals who had TGM7-expression were at increased risk for developing chronic pain, compared to individuals who did not have TGM7-expression.

Another study published in the journal Inflammation Research used TGM7 as a biomarker for chronic pain in individuals with osteoarthritis. The study identified individuals who had TGM7-expression were at increased risk for developing chronic pain, compared to individuals who did not have TGM7-expression.

Conclusion

TGM7 is a promising drug target and biomarker for the treatment of chronic pain. Its ability to identify genes that are associated with chronic pain and its potential as a drug target make it an attractive tool for the development of new treatments for chronic pain. Further research is needed to fully understand the role of TGM7 in the management of chronic pain and to develop safe and effective new treatments for this complex and multifaceted disease.

Protein Name: Transglutaminase 7

Functions: Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins

The "TGM7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TGM7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets